Publication: Drug–drug interactions in adjuvant and neoadjuvant breast cancer therapy
Authors
Miguel Almanchel Rivadeneyra ; Aina Tomás Luiz ; Alonso Romero, José Luis ; Díaz Carrasco, María Sacramento
item.page.secondaryauthor
Facultades de la UMU::Facultad de Medicina
item.page.director
Publisher
BMJ journals
publication.page.editor
publication.page.department
DOI
https://doi.org/10.1136/ejhpharm-2025-004761
item.page.type
info:eu-repo/semantics/article
Description
Abstract
Objective To determine the prevalence, severity and characteristics of potential drug–drug interactions (DDIs) in a homogeneous cohort of patients with early-stage breast cancer receiving adjuvant or neoadjuvant chemotherapy.
Methods We performed a retrospective observational study of patients treated with systemic chemotherapy at a tertiary hospital. All medications prescribed during chemotherapy were recorded. Potential DDIs were identified using the Lexicomp database and classified by risk level, clinical severity, quality of evidence and mechanism of action. Associations between patient-related factors and DDIs were analysed.
Results A total of 273 patients were included (median age 52 years) and 56% had at least one comorbidity. Overall, 2842 drugs were prescribed (median 10 per patient), resulting in 2287 potential DDIs. All patients presented at least one DDI; 89% had at least one type D interaction and 14.6% at least one type X interaction. Most DDIs were classified as type C (75.3%), followed by type D (21.7%) and type X (3.0%). The total number of DDIs was significantly associated with age, comorbidity burden and number of prescribed drugs.
Conclusions Potential DDIs are highly prevalent in patients with early-stage breast cancer receiving chemotherapy, with a substantial proportion involving clinically significant or contraindicated combinations. Polypharmacy, age and comorbidities are key risk factors, highlighting the importance of systematic medication review and interdisciplinary collaboration to improve treatment safety.
publication.page.subject
Citation
Almanchel-Rivadeneyra, M., Romero, J. L. A., Tomás-Luiz, A., & Carrasco, M. S. D. (2026). Drug–drug interactions in adjuvant and neoadjuvant breast cancer therapy. European Journal of Hospital Pharmacy.
item.page.embargo
Collections
Ir a Estadísticas
Sin licencia Creative Commons.